Gamma delta (γδ) T cells are promising candidates for adoptive immunotherapy due to their unique biological and safety profiles. In particular, ex vivo expanded Vγ9Vδ2 T cells engineered with chimeric antigen receptors (CARs) have gained considerable interest, as they combine potent innate-like antitumor activity with a low risk of graft-versus-host disease and cytokine release syndrome, making them ideal for off-the-shelf cancer immunotherapies.
However, as they represent only 1–5% of peripheral T cells, effective activation and expansion protocols are essential to generate sufficient numbers for clinical use. In this study, we describe an automated and highly efficient process for the expansion of Vγ9Vδ2 T cells and the manufacturing of CAR γδ T cells using the CliniMACS Prodigy closed system.
This platform integrates cell separation, activation, genetic modification and expansion ensuring reproducibility and compliance with GMP standards. Starting with an alpha-beta (αβ) T cell and B cell magnetic depletion, we achieved a 4.59-log αβT cell depletion and a 3.97-log B cell depletion.
Frontiers in Immunology published a clinical update in Infectious Disease on 22 May 2026.
The item focuses on A clinical-grade automated platform for the manufacturing of CAR-γδ T cells for immunotherapy.
Review the original article for the full source wording and details.